HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
IMRN
Immuron Limited
There isn't enough reported data to score IMRN yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
IMRN Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
IMRN's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
IMRN PE Valuation
IMRN has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
IMRN Forward outlook
There aren't enough analyst estimates for IMRN to show an outlook.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
IMRN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2022 | -$0.01 | +$0.02 |
IMRN and HIMS do not have enough comparable growth data to identify a winner.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS's revenue has grown year over year every quarter since late 2021: $890M last quarter, up 49% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
IMRN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2025 | $5M | +186% |
| Q2 2024 | $1.7M | +41% |
| Q2 2023 | $1.2M | +136% |
| Q2 2022 | $523.8K | +425% |
| Q2 2021 | $99.8K | -92% |
| Q2 2020 | $1.3M | -20% |
| Q2 2019 | $1.6M | +30% |
| Q2 2018 | $1.3M | +166% |
IMRN has the edge over HIMS in the latest year-over-year revenue comparison.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2025 | -73% | +124 points |
| Q2 2024 | -148% | +227 points |
| Q1 2024 | -148% | +5600 points |
| Q4 2023 | -86% | +67 points |
| Q2 2023 | -198% | -3.7 points |
| Q2 2022 | -375% | -212 points |
| Q2 2021 | -5748% | -5146 points |
| Q2 2020 | -153% | +446 points |
IMRN's operating margin was −73% last quarter, up 124 points from the same quarter a year ago, near the top of its range since 2008.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS still generates free cash flow, though less than at its 2024 peak: $8M over the past year.
IMRN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2024 | -$1.3M | +$455K |
| Q2 2023 | -$1.8M | +$379.9K |
| Q2 2022 | -$2.2M | +$635K |
| Q2 2021 | -$2.8M | -$641.6K |
| Q2 2020 | -$2.2M | -$922.5K |
| Q2 2019 | -$1.2M | +$1.2M |
| Q2 2018 | -$2.4M | +$879.1K |
| Q2 2017 | -$3.3M | -$2.3M |
IMRN has burned cash in almost every quarter: −$7M over the past year, against −$9M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over IMRN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
IMRN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3953% | +225M shares |
| 1 year | +1.4% | +3.1M shares |
| 3 years | +11834% | +229M shares |
IMRN has 231M diluted shares, up 1.4% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2024 | — |
| Q1 2024 | — |
| Q2 2023 | $54,278 |
| Q2 2017 | — |
| Q4 2016 | — |
| Q2 2016 | — |
| Q4 2015 | — |
| Q2 2015 | — |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
IMRN Net Leverage
IMRN's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
IMRN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.6 | Neutral |
| Stochastic | 5.5 | Oversold |
IMRN's weekly RSI is 44 (neutral) and its Stochastic is 6 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
IMRN PE vs Healthcare Sector
IMRN has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
IMRN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.99 | 8.1% below |
| 20 week MA | $1.12 | 19% below |
| 50 week MA | $1.02 | 11% below |
| 100 week MA | $1.44 | 37% below |
| 200 week MA | $1.78 | 49% below |
IMRN is in a downtrend: it's below all five of its weekly moving averages, and 49% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
IMRN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $3.65 | $6.71 | +84% |
| 2021 | $6.71 | $2.90 | -57% |
| 2022 | $2.90 | $1.91 | -34% |
| 2023 | $1.91 | $1.88 | -1.6% |
| 2024 | $1.88 | $1.90 | +1.1% |
| 2025 | $1.90 | $0.89 | -53% |
| 2026 YTD | $0.89 | $0.91 | +2.2% |
IMRN has the edge over HIMS on returns for 2026, with the stronger performance.